Implications of bevacizumab discontinuation in adults with recurrent glioblastoma

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 823-828

  Anderson, Mark D ^a   Hamza, Mohamed A ^a   Hess, Kenneth R ^b   Puduvalli, Vinay K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

bevacizumab; discontinuation; glioblastoma; outcome; recurrence

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IRINOTECAN; ISOTRETINOIN; LOMUSTINE; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ADULT DISEASE; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER FATIGUE; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLIOBLASTOMA; HAZARD ASSESSMENT; HEART INFARCTION; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PROGRESSION FREE SURVIVAL; RETREATMENT; RETROSPECTIVE STUDY; SALVAGE THERAPY; THROMBOCYTOPENIA; TUMOR GROWTH; BRAIN NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84901024412     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou021     Document Type: Article

References (21)

1. Stupp RMW, van den Brent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352:987-996.
2. Wick WHC, Engel C, Stoffels M, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology. 2009;27:5874-5880.
3. GilbertM. Recurrent Glioblastoma: A Fresh Look at Current Therapies and Emerging Novel Approaches. Seminars in Oncology. 2011;38:S21-S33.
4. Wick APC, Wick W, Jauch T, et al. Rechallenge with temozolomide in patients with recurrent gliomas. Journal of Neurology. 2009;256: 734-741.
5. Friedman HSPM,Wen PY, Mikkelsen T, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology. 2009;27:4733-4740.
6. Batchelor TTDD, di Tomaso E, Ancukiewicz M, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of Clinical Oncology. 2010;28:2817-2823.
7. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology. 2009;27:740-745.
8. European Medicines Agency. Refusal Assessment Report for Avastin. London: European Medicines Agency; 2010.
9. Chinot O,WickW, MasonW, et al. Phase III Trial of Bevacizumab Added to Standard Radiotherapy and Temozolomide for Newly-Diagnosed Glioblastoma: Mature Progression-Free Survival and Preliminary Overall Survival Result in Avaglio. Neuro Oncology. 2012;14.
10. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 2013;31.
11. Iwamoto FMAL, Beal K, Gutin PH, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73:1200-1206.
12. Quant ECNA, Drappatz J, Muzikansky A, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncology. 2009;11:550-555.
13. Reardon DA, Peters KB, Vredenburgh JJ, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011;117:5351-5358.
14. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. [abstract 342]. Neuro Oncology. 2005; 7:369.
15. Vredenburgh JJDA, Herndon JE, Dowell JM, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research. 2007;13:1253-1259.
16. Zuniga RMTR, Jain R, Anderson J, et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. Journal of NeuroOncology. 2010;99: 237-242.
17. Wen PYMD, Reardon DA, Cloughesy TF, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology. 2010;28:1963-1972.
18. Pope W, Xia Q, Paton V, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011; 76:432-437.
19. de Groot J. High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More? Clinical Cancer Research. 2011;17:6109-6111.
20. Lorgis V, Maura G, Coppa G, et al. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. Journal of Neurooncology. 2012;107: 351-358.
21. ShermanW, Raizer J, Grimm S. Patterns of Malignant Glioma Relapse after Discontinuing Bevacizumab Prior to Disease Recurrence. Neurology. 2012;78:(P03.138).